Management of candidemia in patients with Clostridium difficile infection

References

• Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373:1445–1456.
   PubMed Web of Science ®Google Scholar
• Guastalegname M, Russo A, Falcone M, et al. Candidemia subsequent to severe infection due to Clostridium difficile: is there a link? Clin Infect Dis. 2013;57:772–774.
   PubMed Web of Science ®Google Scholar
• Russo A, Falcone M, Fantoni M, et al. Risk factors and clinical outcomes of candidemia in patients treated for Clostridium difficile infection. Clin Microbiol Infect. 2015;21:493.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iraci F, et al. Risk factors and outcomes for bloodstream infections secondary to Clostridium difficile infection. Antimicrob Agents Chemother. 2015;60:252–257.
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Almendares O, Farley MM, et al. Epidemiology and factors associated with candidaemia following Clostridium difficile infection in adults within metropolitan Atlanta, 2009–2013. Epidemiol Infect. 2016;144:1440–1444.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46:S12–S18.
   PubMed Web of Science ®Google Scholar
• Crobach MJ, Dekkers OM, Wilcox MH, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1053–1066.
   PubMed Web of Science ®Google Scholar
• Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Treatment guidance for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–1079.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441.
   PubMed Web of Science ®Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile: more difficult than ever. N Engl J Med. 2008;359:1932–1940.
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile, EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.
   PubMed Web of Science ®Google Scholar
• Falcone M, Iraci F, Raponi G, et al. Nursing-home residence is associated with Clostridium difficile PCR ribotype-027 spread in Central Italy. J Hosp Infect. 2016. Submitted.
   Google Scholar
• Andes DR, Safdar N, Baddley JW, et al; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–1122.
   PubMed Web of Science ®Google Scholar
• Lederberg J, McCray AT. ‘Ome Sweet ‘Omics – a genealogical treasury of words. Scientist. 2001;15:8.
   Web of Science ®Google Scholar
• Pfeiffer JK, Virgin HW. Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science. 2016;351. doi: 10.1126/science.aad5872
   Web of Science ®Google Scholar
• Segata N, Haake SK, Mannon P, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;13:R42.
   PubMed Web of Science ®Google Scholar
• Rashid MU, Weintraub A, Nord CE. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe. 2012;18:249–253.
   PubMed Web of Science ®Google Scholar
• Young VB, Britton RA. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology. 2014;146:1547–1553.
   PubMed Web of Science ®Google Scholar
• Rashid MU, Zaura E, Buijs MJ, et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Infect Dis. 2015;60:S77–S84.
   PubMed Web of Science ®Google Scholar
• Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;2:119–128.
   Google Scholar
• Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis. 1996;22:S73–S88.
   PubMed Web of Science ®Google Scholar
• Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol. 2013;21:334–341.
   PubMed Web of Science ®Google Scholar
• Raponi G, Visconti V, Brunetti G, et al. Clostridium difficile infection and Candida colonization of the gut: is there a correlation? Clin Infect Dis. 2014;59:1648–1649.
   PubMed Web of Science ®Google Scholar
• Nerandzic MM, Mullane K, Miller MA, et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012;55:S121–S126.
   PubMed Web of Science ®Google Scholar
• Warren CA, van Opstal EJ, Riggins MS, et al. Vancomycin treatment’s association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013;57:689–696.
   PubMed Web of Science ®Google Scholar
• Lewis BB, Buffie CG, Carter RA, et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis. 2015;212:1656–1665.
   PubMed Web of Science ®Google Scholar
• Zollner-Schwetz I, Auner HW, Paulitsch A, et al. Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation. J Infect Dis. 2008;198:150–153.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51:e38–e45.
   PubMed Web of Science ®Google Scholar
• Madan R, Petri WA Jr. Immune responses to Clostridium difficile infection. Trends Mol Med. 2012;18:658–666.
   PubMed Web of Science ®Google Scholar
• Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61:233–241.
   PubMed Web of Science ®Google Scholar
• Luzzati R, Cavinato S, Giangreco M, et al. Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial candidemia in elderly patients: a matched case–control study. Mycoses. 2013;56:664–671.
   PubMed Web of Science ®Google Scholar
• Tascini C, Sozio E, Tintori G, et al. Peripherally inserted central catheter as a predominant risk factor for candidemia in critically ill patients in internal medicine wards in Italy. Intensive Care Med. 2015;41:1498–1499.
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.
   PubMed Web of Science ®Google Scholar
• Falcone M, Accarpio F, Venditti M, et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J Antimicrob Chemother. 2010;65:2266–2267.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Erstad BL, Petty W, et al. Time to positive culture and identification for Candida bloodstream infections. Diagn Microbiol Infect Dis. 2009;64:402–407.
   PubMed Web of Science ®Google Scholar
• León C, Ruiz-Santana S, Saavedra P, et al; EPCAN Study Group. A bedside scoring system (“Candida score”) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730–737.
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7–15.
   PubMed Web of Science ®Google Scholar
• Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care. 2011;15:R249.
   PubMed Web of Science ®Google Scholar
• Giglio M, Caggiano G, Dalfino L, et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomised clinical trial. Crit Care. 2012;16:R57.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Giuliano S, Falcone M, et al. Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation. Crit Care. 2013;17:414.
   PubMed Web of Science ®Google Scholar
• Austin N, Cleminson J, Darlow BA, et al. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev. 2015;10:CD003478.
   PubMedGoogle Scholar
• Mersal A, Alzahrani I, Azzouz M, et al. Oral nystatin versus intravenous fluconazole as neonatal antifungal prophylaxis: non-inferiority trial. J Clin Neonatol. 2013;2:88–92.
   PubMedGoogle Scholar
• Desai MH, Rutan RL, Heggers JP, et al. Candida infection with and without nystatin prophylaxis. A 11-year experience with patients with burn injury. Arch Surg. 1992;17:159–162.
   Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55:S132–S142.
   PubMed Web of Science ®Google Scholar
• Humphreys DP, Wilcox MH. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol. 2014;21:913–923.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822–831.
   PubMed Web of Science ®Google Scholar
• Baliban SM, Michael A, Shammassian B, et al. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun. 2014;82:4080–4091.
   PubMed Web of Science ®Google Scholar
• Karczewski J, Zorman J, Wang S, et al. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine. 2014;32:2812–2818.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–e50.
   PubMed Web of Science ®Google Scholar
• Ricardo E, Miranda IM, Faria-Ramos I, et al. In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. Antimicrob Agents Chemother. 2014;58:4604–4611.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49:668–679.
   PubMed Web of Science ®Google Scholar
• Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2013;57:4053–4057.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro P, Posteraro B. Echinocandin antifungal drug resistance in Candida species: a cause for concern? Curr Infect Dis Rep. 2010;12:437–443.
   PubMedGoogle Scholar
• Shields RK, Nguyen MH, Press EG, et al. Presence of an FSK mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862–4869.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs. 2003;12:1313–1333.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xiao M, Watts MR, et al. Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. BMC Infect Dis. 2015;15:340.
   PubMed Web of Science ®Google Scholar
• Branco J, Silva AP, Silva RM, et al. Fluconazole and voriconazole resistance in Candida parapsilosis is conferred by gain-of-function mutations in MRR1 transcription factor gene. Antimicrob Agents Chemother. 2015;59:6629–6633.
   PubMed Web of Science ®Google Scholar
• Rupnik M. Toward a true bacteriotherapy for Clostridium difficile infection. N Engl J Med. 2015;372:1566–1568.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.
   PubMed Web of Science ®Google Scholar
• Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21:230–237.
   PubMed Web of Science ®Google Scholar
• Moore T, Rodriguez A, Bakken JS. Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin Infect Dis. 2014;58:541–545.
   PubMed Web of Science ®Google Scholar